How long will patients with glioblastoma survive?
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
How long will patients with glioblastoma survive?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
How long will patients with glioblastoma survive? How do patients with glioma survive longer?
According to the World Health Organization (WHO) pathological classification of glioma, glioblastoma in WHO grade 4 is a highly malignant tumor.
Past research data shows that the median survival time of patients with glioblastoma At 18 months, glioblastoma is still an incurable disease.
To improve the survival rate of patients with high-grade glioma, new breakthroughs in treatment are still needed.
How many years can malignant glioma live? Treatment is the key
The main methods of treatment of glioblastoma are surgery, radiotherapy and chemotherapy. There is no doubt that the scope of surgical resection of tumors is a key factor affecting the survival rate of patients.
As early as 1978, radiotherapy was discovered as a way to prolong the survival of patients with high-grade glioma;
The chemotherapeutic drug temozolomide was confirmed to be used for the treatment of recurrent high-grade glioma in 2000, and was approved for primary glioblastoma in 2005;
Bevacizumab was first approved in 2008 for the treatment of recurrent glioblastoma.
In addition, there are some new therapeutic drugs that have been clinically tested, such as cytotoxic chemotherapy drugs, anti-angiogenesis drugs, signal transduction modifiers, biological agents and immunotherapy. Each treatment method improves the survival rate of patients. Has been gradually improved.
Table 1: Potential molecular targets for glioblastoma
In recent years, a non-drug therapy has begun to show moderate survival benefits in the field of malignant tumor treatment. It is precision targeted therapy.
With the deepening of the understanding of the molecular subtypes, genomic changes, main molecular markers and signal pathways of glioblastoma in the field of neurosurgery, more accurate diagnosis and prediction of different subtypes of glioma can be made.
For example: IDH1 and IDH2 mutations are an important clue for the evolution of tumors from low-grade gliomas to high-grade gliomas; about 1%-3% of glioblastomas carry NTRK1 gene fusion; 3% of astrocytes The tumor carries NTRK2 gene fusion,
These research results will provide more information for the precise targeted therapy of high-grade gliomas.
How long will patients with glioblastoma survive?
(source:internet, reference only)
Disclaimer of medicaltrend.org
